Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

IPSS-R for MDS

The IPSS-R defines risk groups for survival and risk of AML evolution in untreated MDS patients.

Evidence-based context for fast calculator use

Purpose:
IPSS-R stratifies myelodysplastic syndrome patients by survival and AML transformation risk to guide transplant and treatment timing.
Population:
patients with the specific hematologic diagnosis and disease phase described by the model
Factors:
Cytogenetic Risk Group, Bone Marrow Blasts, Hemoglobin, Platelets, ANC
Reference:
Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-2465.
HomeIPSS-R for MDS
Pin your most used calculators here by clicking the star in the dropdown.

IPSS-R for MDS

%
g/dL
x10⁹/L
x10⁹/L

Clinical Context & Background

The IPSS-R defines risk groups for survival and risk of AML evolution in untreated MDS patients. It includes cytogenetics, bone marrow blasts, hemoglobin, platelets, and ANC. Note: The molecular IPSS-M (2022) provides further refinement if NGS data is available.
Primary Source EvidenceGreenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-2465.
Formula Logic
Sum of weighted points from 5 variables.

Reference Data

Risk GroupTotal ScoreMedian Survival
Very Low≤ 1.58.8 years
Low> 1.5 - 35.3 years
Intermediate> 3 - 4.53.0 years
High> 4.5 - 61.6 years
Very High> 60.8 years

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use IPSS-R for MDS when iPSS-R stratifies myelodysplastic syndrome patients by survival and AML transformation risk to guide transplant and treatment timing.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning Very Low through Very High.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm morphology, molecular/cytogenetic data, treatment timing, laboratory units, and the current disease-specific guideline before acting.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Hematology scores are diagnosis-, phase-, and treatment-specific and should not be transferred between diseases.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients with the specific hematologic diagnosis and disease phase described by the model

How to apply this result

For a representative case, verify Cytogenetic Risk Group, Bone Marrow Blasts, Hemoglobin, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Hematology hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

NCCN-IPI (Lymphoma)CLL-IPIMIPI (Mantle Cell Lymphoma)

Frequently Asked Questions

When should IPSS-R for MDS be used?

Use it for patients with the specific hematologic diagnosis and disease phase described by the model when all required inputs and the intended clinical setting are confirmed.

Can IPSS-R for MDS determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.